Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Three beta3-adrenoceptor agonists in preclinical stage at BMS

April 26, 1996

MTP inhibitor BMS-201038 in development for hyperlipidemia

April 26, 1996

Colestimide NDA filing imminent

April 26, 1996

Otsuka evaluates hypolipidemic agents

April 26, 1996

Sanofi Winthrop discovers potent ATP-citrate lyase inhibitor

April 26, 1996

NTE-122: Nissin Foods' ACAT inhibitor

April 26, 1996

FemPatch approval imminent in USA

April 19, 1996

FDA designates orphan drug for Peyronie's disease

April 19, 1996

Troglitazone NDA filing expected soon

April 19, 1996

RF-1051 cleared to enter phase II

April 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...